Edit

Longitude Capital

https://www.longitudecapital.com
Last activity: 16.03.2025
Active
Invests in categories: MedTechHealthTechCareBioTechProductDevelopmentHardwareTechnologyPlatformLife
Longitude Capital is a healthcare venture capital firm that invests in transformative healthcare companies to unlock value and enable growth.
Portfolio
79
Mentions
63
Investment Type: Venture Capital
Investment Stage: Series C

Portfolio 79

DateNameWebsiteTotal RaisedLocation
25.03.2024BioAge Lab...bioagelabs.com$270.9MUnited Sta...
25.03.2024Tourmaline...tourmalinebio.com$75MUnited Sta...
10.01.2024Lassen The...lassentherapeutics.com$85MUnited Sta...
09.11.2023OrsoBioorsobio.com$129.3MUnited Sta...
25.10.2023Kala Pharm...kalarx.com$218.2MUnited Sta...
25.10.2023Mirum Phar...mirumpharma.com$120MUnited Sta...
09.04.2023TreatMyOCDtreatmyocd.com$50MUnited Sta...
01.02.2023NOCDnocd.com$34M-
07.12.2022Opna Bioopnabio.com$38M-
17.11.2022Zenas BioP...zenasbio.com$318MUnited Sta...
Show more

Mentions in press and media 63

DateTitleDescription
17.03.2025MicroTransponder Secures $65 Million to Revolutionize Stroke RecoveryIn the heart of Austin, Texas, a medical device company is making waves. MicroTransponder has just raised $65 million in Series F funding. This investment is a significant step forward in the company’s mission to transform stroke recovery. ...
16.03.2025MicroTransponder: $65 Million (Series F) Raised For Enhancing Vivistim Adoption For Chronic Stroke RecoveryMicroTransponder – which is one of the fastest-growing stroke companies – announced it is transforming the stroke continuum of care with its FDA-approved Vivistim Paired VNS System. The company also announced it has raised $75 million led b...
13.03.2025MicroTransponder Raises $65M in Series F FundingMicroTransponder, an Austin, TX-based medical device company, raised $65M in Series F funding. The round was led by US Venture Partners (USVP) and the syndicate of current investors, Osage University Partners, Action Potential Venture Capit...
13.02.2025Helicore Biopharma: $65 Million (Series A) Raised For Glucose-Dependent Insulinotropic Peptide PlatformHelicore Biopharma, a biopharmaceutical company focused on discovering and developing first-in-class glucose-dependent insulinotropic peptide (GIP) antagonists for obesity and related conditions, announced its emergence from stealth mode wi...
09.01.2025FIRE1: $120 Million Funding Raised For Transforming Heart Failure CareFIRE1 – a leading connected medical device solutions company – announced the completion of a $120 million financing round to accelerate the company’s mission to transform the lives of millions of people living with heart failure. The fundin...
08.01.2025FIRE1 Secures $120M for Heart Failure Management PlatformWhat You Should Know: – FIRE1, a connected medical device company, announced it has secured $120M in funding to advance its mission to transform the lives of millions of people living with heart failure. The round was led by Polaris Partner...
07.01.2025Jeito Capital's Bold Moves in Biopharma: A Strategic Investment LandscapeIn the world of biopharma, where innovation is the lifeblood, Jeito Capital is making waves. This Paris-based private equity fund is not just dipping its toes; it’s diving deep into the ocean of clinical-stage biotech. With a recent investm...
07.01.2025FIRE1 heats up with $120M for its heart failure monitor implantThings are heating up for FIRE1, which posted a $120 million funding round to support its implant for tracking the hidden signs of heart failure. The Dublin-based company also announced that the FDA has handed down a breakthrough designatio...
07.01.2025Aviceda raises $207M series C to take geographic atrophy drug through phase 3Aviceda Therapeutics has secured $207.5 million in series C funds as the immunomodulator-focused biotech awaits a phase 3 readout this year for its lead eye disease drug. The round was co-led by the healthcare funds Omega Funds and TCGX, wi...
07.01.2025FIRE1 Secures $120M FinancingFIRE1, a Dublin, Ireland-based connected medical device solutions company, raised $120M in funding. The round was led by Polaris Partners and Elevage Medical Technologies, joined by new investors Sands Capital and Longitude Capital, and exi...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In